Chemistry:ACP-105
From HandWiki
Short description: Chemical compound
 | |
| Legal status | |
|---|---|
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C16H19ClN2O |
| Molar mass | 290.79 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
ACP-105 is a drug which acts as a selective androgen receptor modulator (SARM). It has been investigated for potential use in the treatment of age-related cognitive decline.[1][2][3][4] The drug has been found to reduce anxiety-like behavior in a mouse model of Alzheimer's disease when administered alone, as well as enhance spatial memory when coadministered with the selective estrogen receptor β agonist AC-186.[3] ACP-105 is an aniline SARM and is related to AC-262536 and vosilasarm (RAD140).[5]
References
- ↑ "Synthesis, structure-activity relationships, and characterization of novel nonsteroidal and selective androgen receptor modulators". Journal of Medicinal Chemistry 52 (22): 7186–7191. November 2009. doi:10.1021/jm901149c. PMID 19856921.
- ↑ "Effects of the SARM ACP-105 on rotorod performance and cued fear conditioning in sham-irradiated and irradiated female mice". Brain Research 1381: 134–140. March 2011. doi:10.1016/j.brainres.2010.12.088. PMID 21219889.
- ↑ 3.0 3.1 "Nonsteroidal selective androgen receptor modulators and selective estrogen receptor β agonists moderate cognitive deficits and amyloid-β levels in a mouse model of Alzheimer's disease". ACS Chemical Neuroscience 4 (12): 1537–1548. December 2013. doi:10.1021/cn400133s. PMID 24020966.
- ↑ "Identification of equine in vitro metabolites of seven non-steroidal selective androgen receptor modulators for doping control purposes". Drug Testing and Analysis 14 (2): 349–370. October 2021. doi:10.1002/dta.3189. PMID 34714606. https://biblio.ugent.be/publication/8740373/file/8740375.
- ↑ "Deciphering the selective androgen receptor modulators paradigm". Expert Opinion on Drug Discovery 8 (2): 191–218. February 2013. doi:10.1517/17460441.2013.741582. PMID 23231475.
 |  |
